Atlas Trials

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

Clinical trial NCT05939648 · UNKNOWN

Trial details

NCT number
NCT05939648
Sponsor
AIM Vaccine Co., Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
SARS-CoV-2
Start date
2023-10-09
Primary completion
2023-11-30
Enrollment
450

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.